CVS Caremark Reports Record Second Quarter Results 2013 GUIDANCE RANGE NARROWED PRIMARILY TO REFLECT TIMING OF SHARE REPURCHASES AND STRONG OPERATING RESULTS

WOONSOCKET, R.I., Aug. 6, 2013 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) today announced operating results for the three months ended June 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

Second Quarter Year-over-year Highlights:

  • Operating profit increased 15.2% to approximately $2.0 billion
  • Adjusted EPS increased 19.6% to $0.97; GAAP diluted EPS from continuing operations increased 20.8% to $0.91
  • Retail pharmacy same store prescription volumes increased 1.8%, or 5.0% on a 30-day equivalent basis
  • Retail pharmacy same store sales increased 0.8%; total same store sales increased 0.4%

Year-to-date Highlights:

  • Generated free cash flow of $1.7 billion
  • Cash flow from operations of $2.5 billion

2013 Guidance:

  • Narrowed 2013 full-year Adjusted EPS range to $3.90 to $3.96 and GAAP diluted EPS from continuing operations range to $3.65 to $3.71
  • Provided third quarter Adjusted EPS guidance of $1.00 to $1.03 and GAAP diluted EPS from continuing operations guidance of $0.94 to $0.97
  • Expect full year free cash flow of $4.8 to $5.1 billion and cash flow from operations of $6.4 to $6.6 billion

Revenues

Net revenues for the three months ended June 30, 2013, increased 1.7%, or $534 million, compared to the three months ended June 30, 2012.

Revenues in the Pharmacy Services Segment increased 2.0%, or $377 million, in the three months ended June 30, 2013. The growth was primarily driven by volume increases across all channels and drug cost inflation in our specialty pharmacy business, partially offset by the impact of new generic introductions. Pharmacy network claims processed during the three months ended June 30, 2013, increased 4.1% to 205.9 million, compared to 197.8 million in the prior year period. The increase in pharmacy network claims was primarily due to additional claims activity associated with new clients. Mail choice claims processed during the three months ended June 30, 2013, increased approximately 1.0% to 20.7 million, compared to 20.5 million in the prior year period. The increase in the mail choice claim volume was primarily due to increased claims associated with the continuing adoption of our Maintenance Choice® offerings.

Revenues in the Retail Pharmacy Segment increased 1.9%, or $293 million, in the three months ended June 30, 2013. Same store sales increased 0.4% when compared to the prior year period, with pharmacy same store sales up 0.8% and front store same store sales down 0.4%. The increase in same store sales was primarily driven by same store prescription volumes, partially offset by new generic drug introductions and the shift of the Easter holiday from April in 2012 to March in 2013. Pharmacy same store prescription volumes rose 1.8% when 90-day prescriptions are counted as one prescription. On a 30-day equivalent basis, same store prescription volumes increased 5.0% in the quarter. Pharmacy same store sales were negatively impacted by approximately 670 basis points due to recent generic introductions. Front store same store sales were negatively impacted by approximately 65 basis points due to the shift of the Easter holiday.

For the three months ended June 30, 2013, the generic dispensing rate increased approximately 270 basis points in our Pharmacy Services Segment, to 80.7%, and approximately 280 basis points in our Retail Pharmacy Segment, to 81.9%, compared to the prior year period.

Income from Continuing Operations Attributable to CVS Caremark

Income from continuing operations attributable to CVS Caremark for the three months ended June 30, 2013, increased 15.9%, or approximately $154 million, to $1.1 billion, compared with $967 million during the three months ended June 30, 2012. The increase in income from continuing operations was primarily driven by the positive impact from new generics, which significantly improved operating profit in both our Pharmacy Services and Retail Pharmacy segments. Adjusted earnings per share from continuing operations attributable to CVS Caremark (Adjusted EPS) for the three months ended June 30, 2013 and 2012, was $0.97 and $0.81, respectively, an increase of 19.6%. Adjusted EPS excludes $124 million and $123 million of intangible asset amortization related to acquisition activity in the three months ended June 30, 2013, and 2012, respectively. GAAP earnings per diluted share from continuing operations attributable to CVS Caremark for the three months ended June 30, 2013, and 2012, was $0.91 and $0.75, respectively, an increase of 20.8%.

President and Chief Executive Officer Larry Merlo said, "Our second quarter results reflect very strong operating performance, with operating profit increasing 15% enterprise-wide, with 32% growth in the PBM and 9% growth in the retail business. As expected, new generic drug introductions continued to be a significant growth driver across the enterprise, resulting in healthy margin expansion and earnings growth. We achieved Adjusted EPS for the quarter at the high end of our guidance range despite a higher-than-anticipated share count."

Mr. Merlo continued, "A primary reason for our higher-than-anticipated share count is that we suspended share repurchases during part of the second quarter while we were engaged in negotiations with the SEC concerning the agreement in principle we announced last week. However, we remain committed to returning significant value to our shareholders through both dividends and share repurchases. We have delivered $1.7 billion in free cash flow year-to-date and we expect to complete our planned $4 billion in share repurchases during 2013."

Real Estate Program

During the three months ended June 30, 2013, the Company opened 23 new retail drugstores, and closed one retail drugstore and one retail specialty pharmacy store. In addition, the Company relocated 24 retail drugstores. As of June 30, 2013, the Company operated 7,617 locations in 45 states, the District of Columbia, Puerto Rico and Brazil. These locations included 7,553 retail drugstores, 18 onsite pharmacies, 30 retail specialty pharmacy stores, 12 specialty mail order pharmacies and four mail service pharmacies.

Guidance

The Company narrowed its earnings guidance range for the full year 2013, primarily to reflect the timing of share repurchases and strong operating results. The Company completed $355 million in share repurchases during the second quarter and $748 million year to date, which is less than originally anticipated. These 2013 guidance estimates assume the completion of approximately $4 billion in previously authorized share repurchases this year. However, with share repurchases back-half weighted as opposed to occurring ratably throughout the year as originally anticipated, this timing shift is estimated to dampen the accretive impact on the Company's EPS in 2013 by as much as 4 cents per share. The Company currently expects to deliver Adjusted EPS of $3.90 to $3.96 and GAAP diluted earnings per share from continuing operations of $3.65 to $3.71 per share in 2013. The Company expects to deliver 2013 free cash flow of $4.8 billion to $5.1 billion, and 2013 cash flow from operations guidance of $6.4 billion to $6.6 billion.

Teleconference and Webcast

The Company will be holding a conference call today for the investment community at 8:30 am (EDT) to discuss its quarterly results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Caremark website at http://info.cvscaremark.com/investors. This webcast will be archived and available on the website for a one-year period following the conference call.

About the Company

CVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the Company's more than 7,500 retail pharmacy stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 650 MinuteClinic® locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans. As a pharmacy innovation company with an unmatched breath of capabilities, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor® program that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about how CVS Caremark is reinventing pharmacy for better health at http://info.cvscaremark.com/.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.

— Tables Follow —

 

CVS CAREMARK CORPORATION

Condensed Consolidated Statements of Income

(Unaudited)




Three Months Ended

June 30,


Six Months Ended

June 30,

In millions, except per share amounts


2013


2012


2013


2012










Net revenues


$

31,248



$

30,714



$

62,011



$

61,512


Cost of revenues


25,412



25,265



50,593



50,950


Gross profit


5,836



5,449



11,418



10,562


Operating expenses


3,868



3,741



7,751



7,451


Operating profit


1,968



1,708



3,667



3,111


Interest expense, net


126



132



252



263


Income before income tax provision


1,842



1,576



3,415



2,848


Income tax provision


720



610



1,337



1,106


Income from continuing operations


1,122



966



2,078



1,742


Loss from discontinued operations, net of tax


(1)



(1)



(1)



(2)


Net income


1,121



965



2,077



1,740


Net loss attributable to noncontrolling interest




1





2


Net income attributable to CVS Caremark


$

1,121



$

966



$

2,077



$

1,742











Income from continuing operations attributable to CVS Caremark:









Income from continuing operations


$

1,121



$

966



$

2,077



$

1,742


Net loss attributable to noncontrolling interest




1





2


Income from continuing operations attributable to CVS Caremark


$

1,121



$

967



$

2,077



$

1,744











Basic earnings per common share:









Income from continuing operations attributable to CVS Caremark


$

0.91



$

0.76



$

1.69



$

1.35


Loss from discontinued operations attributable to CVS Caremark









Net income attributable to CVS Caremark


$

0.91



$

0.76



$

1.69



$

1.35


Weighted average basic common shares outstanding


1,227



1,278



1,230



1,289











Diluted earnings per common share:









Income from continuing operations attributable to CVS Caremark


$

0.91



$

0.75



$

1.68



$

1.34


Loss from discontinued operations attributable to CVS Caremark









Net income attributable to CVS Caremark


$

0.91



$

0.75



$

1.68



$

1.34


Weighted average diluted common shares outstanding


1,236



1,287



1,238



1,298











Dividends declared per common share


$

0.2250



$

0.1625



$

0.4500



$

0.3250



 

CVS CAREMARK CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)




June 30,


December 31,

In millions, except per share amounts


2013


2012

Assets:





Cash and cash equivalents


$

1,174



$

1,375


Short-term investments


5



5


Accounts receivable, net


7,093



6,473


Inventories


10,578



10,759


Deferred income taxes


606



663


Other current assets


413



577


Total current assets


19,869



19,852


Property and equipment, net


8,708



8,632


Goodwill


26,554



26,395


Intangible assets, net


9,657



9,753


Other assets


1,496



1,280


Total assets


$

66,284



$

65,912







Liabilities:





Accounts payable


$

5,178



$

5,070


Claims and discounts payable


3,993



3,974


Accrued expenses


3,501



4,051


Short-term debt




690


Current portion of long-term debt


18



5


Total current liabilities


12,690



13,790


Long-term debt


9,358



9,133


Deferred income taxes


3,796



3,784


Other long-term liabilities


1,534



1,501


Commitments and contingencies










Shareholders' equity:





Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding





Common stock, par value $0.01: 3,200 shares authorized; 1,676 shares issued and





1,227 shares outstanding at June 30, 2013 and 1,667 shares issued and 1,231 shares





outstanding at December 31, 2012


17



17


Treasury stock, at cost: 448 shares at June 30, 2013 and 435 shares at December 31,





2012


(16,987)



(16,270)


Shares held in trust: 1 share at June 30, 2013 and December 31, 2012


(31)



(31)


Capital surplus


29,532



29,120


Retained earnings


26,573



25,049


Accumulated other comprehensive loss


(198)



(181)


Total shareholders' equity


38,906



37,704


Total liabilities and shareholders' equity


$

66,284



$

65,912


 


CVS CAREMARK CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)




Six Months Ended

June 30,

In millions


2013


2012

Cash flows from operating activities:





Cash receipts from customers


$

56,446



$

57,644


Cash paid for inventory and prescriptions dispensed by retail network pharmacies


(44,657)



(45,289)


Cash paid to other suppliers and employees


(7,452)



(7,134)


Interest received


2



1


Interest paid


(267)



(281)


Income taxes paid


(1,530)



(924)


Net cash provided by operating activities


2,542



4,017







Cash flows from investing activities:





Purchases of property and equipment


(804)



(818)


Proceeds from sale of property and equipment


11




Acquisitions (net of cash acquired) and other investments


(300)



(274)


Proceeds from sale of subsidiary




7


Net cash used in investing activities


(1,093)



(1,085)







Cash flows from financing activities:





Decrease in short-term debt


(690)



(550)


Repayments of long-term debt




(54)


Purchase of noncontrolling interest in subsidiary




(26)


Dividends paid


(553)



(420)


Proceeds from exercise of stock options


309



518


Excess tax benefits from stock-based compensation


34



8


Repurchase of common stock


(748)



(1,998)


Net cash used in financing activities


(1,648)



(2,522)


Effect of exchange rates on cash


(2)




Net increase (decrease) in cash and cash equivalents


(201)



410


Cash and cash equivalents at the beginning of the year


1,375



1,413


Cash and cash equivalents at the end of the year


$

1,174



$

1,823







Reconciliation of net income to net cash provided by operating activities:





Net income


$

2,077



$

1,740


Adjustments required to reconcile net income to net cash provided by operating activities:





Depreciation and amortization


951



854


Stock-based compensation


66



64


Deferred income taxes and other non-cash items


82



83


Change in operating assets and liabilities, net of effects of acquisitions:





Accounts receivable, net


(575)



(13)


Inventories


204



(527)


Other current assets


165



254


Other assets


(138)



(181)


Accounts payable and claims and discounts payable


98



655


Accrued expenses


(412)



1,095


Other long-term liabilities


24



(7)


Net cash provided by operating activities


$

2,542



$

4,017


 

Adjusted Earnings Per Share

(Unaudited)

For internal comparisons, management finds it useful to assess year-over-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.

The Company defines adjusted earnings per share as income before income tax provision plus amortization, less adjusted income tax provision, plus net loss attributable to noncontrolling interest divided by the weighted average diluted common shares outstanding.

The following is a reconciliation of income before income tax provision to adjusted earnings per share:




Three Months Ended

June 30,


Six Months Ended

June 30,

In millions, except per share amounts


2013


2012


2013


2012










Income before income tax provision


$

1,842



$

1,576



$

3,415



$

2,848


Amortization


124



123



246



241


Adjusted income before income tax provision


1,966



1,699



3,661



3,089


Adjusted income tax provision(1) 


769



658



1,433



1,199


Adjusted income from continuing operations


1,197



1,041



2,228



1,890


Net loss attributable to noncontrolling interest




1





2


Adjusted income from continuing operations attributable to









CVS Caremark


$

1,197



$

1,042



$

2,228



$

1,892











Weighted average diluted common shares outstanding


1,236



1,287



1,238



1,298


Adjusted earnings per share from continuing operations









attributable to CVS Caremark


$

0.97



$

0.81



$

1.80



$

1.46



(1) The adjusted income tax provision is computed using the effective income tax rate from the consolidated statement of income.



 


Free Cash Flow

(Unaudited)

The Company defines free cash flow as net cash provided by operating activities less net additions to properties and equipment (i.e., additions to property and equipment plus proceeds from sale-leaseback transactions).

The following is a reconciliation of net cash provided by operating activities to free cash flow:




Six Months Ended

June 30,

In millions


2013


2012






Net cash provided by operating activities


$

2,542



$

4,017


Subtract: Additions to property and equipment


(804)



(818)


Free cash flow


$

1,738



$

3,199


 

Supplemental Information

(Unaudited)

The Company evaluates its Pharmacy Services and Retail Pharmacy Segment performance based on net revenue, gross profit and operating profit before the effect of nonrecurring charges and gains and certain intersegment activities. The Company evaluates the performance of its Corporate Segment based on operating expenses before the effect of nonrecurring charges and gains and certain intersegment activities. The following is a reconciliation of the Company's segments to the accompanying consolidated financial statements:


In millions


Pharmacy 

Services

Segment(1)


Retail 

Pharmacy 

Segment


Corporate 

Segment


Intersegment 

Eliminations(2)


Consolidated

Totals

Three Months Ended











June 30, 2013:











Net revenues


$

18,800



$

16,139



$



$

(3,691)



$

31,248


Gross profit


963



5,000





(127)



5,836


Operating profit (loss)


675



1,596



(176)



(127)



1,968


June 30, 2012:











Net revenues


18,423



15,846





(3,555)



30,714


Gross profit


777



4,769





(97)



5,449


Operating profit (loss)


511



1,469



(175)



(97)



1,708


Six Months Ended











June 30, 2013:











Net revenues


37,111



32,191





(7,291)



62,011


Gross profit


1,731



9,952





(265)



11,418


Operating profit (loss)


1,174



3,133



(375)



(265)



3,667


June 30, 2012:











Net revenues


36,722



31,869





(7,079)



61,512


Gross profit


1,393



9,341





(172)



10,562


Operating profit (loss)


860



2,766



(343)



(172)



3,111


Total Assets:











June 30, 2013


36,271



29,639



1,364



(990)



66,284


December 31, 2012


36,057



29,183



1,408



(736)



65,912


Goodwill:











June 30, 2013


19,658



6,896







26,554


December 31, 2012


19,646



6,749







26,395



































(1)

Net revenues of the Pharmacy Services Segment include approximately $2.0 billion and $2.1 billion of retail co-payments for the three months ended June 30, 2013 and 2012, respectively, as well as $4.2 billion and $4.4 billion of retail co-payments for the six months ended June 30, 2013 and 2012, respectively.

(2)

Intersegment eliminations relate to two types of transaction: (i) Intersegment revenues that occur when Pharmacy Services Segment customers use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment customers, through the Company's intersegment activities (such as the Maintenance Choice program), elect to pick-up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $1.1 billion and $840 million for the three months ended June 30, 2013 and 2012, respectively, and $2.0 billion and $1.6 billion for the six months ended June 30, 2013 and 2012, respectively; gross profit and operating profit of $127 million and $97 million for the three months ended June 30, 2013 and 2012, respectively, and $265 million and $172 million for the six months ended June 30, 2013 and 2012, respectively.

 

Supplemental Information

(Unaudited)

 

Pharmacy Services Segment

The following table summarizes the Pharmacy Services Segment's performance for the respective periods:




Three Months Ended

June 30,


Six Months Ended

June 30,

In millions


2013


2012


2013


2012










Net revenues


$

18,800



$

18,423



$

37,111



$

36,722


Gross profit


963



777



1,731



1,393


Gross profit % of net revenues


5.1

%


4.2

%


4.7

%


3.8

%

Operating expenses


288



266



557



533


Operating expense % of net revenues


1.5

%


1.4

%


1.5

%


1.5

%

Operating profit


675



511



1,174



860


Operating profit % of net revenues


3.6

%


2.8

%


3.2

%


2.3

%

Net revenues(1):









Mail choice(2)


$

6,036



$

5,744



$

11,905



$

11,410


Pharmacy network(3)


12,709



12,625



25,100



25,209


Other


55



54



105



103


Pharmacy claims processed(1):









Total


226.6



218.3



454.3



437.2


Mail choice(2)


20.7



20.5



41.3



40.9


Pharmacy network(3)


205.9



197.8



413.0



396.3


Generic dispensing rate(1):









Total


80.7

%


78.0

%


80.6

%


77.3

%

Mail choice(2)


75.8

%


71.2

%


75.6

%


70.1

%

Pharmacy network(3)


81.1

%


78.6

%


81.0

%


78.0

%

Mail choice penetration rate


22.4

%


22.9

%


22.3

%


22.9

%

(1)

Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category.

(2)

Mail choice is defined as claims filled at a Pharmacy Services mail facility, which include specialty mail claims, as well as 90-day claims filled at retail under the Maintenance Choice program.

(3)

Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity.

 

Supplemental Information

(Unaudited)

Retail Pharmacy Segment

The following table summarizes the Retail Pharmacy Segment's performance for the respective periods:




Three Months Ended

June 30,


Six Months Ended

June 30,

In millions


2013


2012


2013


2012










Net revenues


$

16,139



$

15,846



$

32,191



$

31,869


Gross profit


5,000



4,769



9,952



9,341


Gross profit % of net revenues


31.0

%


30.1

%


30.9

%


29.3

%

Operating expenses


3,404



3,300



6,819



6,575


Operating expense % of net revenues


21.1

%


20.8

%


21.2

%


20.6

%

Operating profit


1,596



1,469



3,133



2,766


Operating profit % of net revenues


9.9

%


9.3

%


9.7

%


8.7

%

Retail prescriptions filled (90 Day = 1Rx)


181.1



176.4



365.8



355.9


Retail prescriptions filled (90 Day = 3 Rx) (1)


220.3



208.5



441.8



418.5


Net revenue increase:









Total


1.9

%


6.9

%


1.0

%


8.4

%

Pharmacy


2.2

%


8.3

%


0.5

%


9.7

%

Front store


1.1

%


3.9

%


2.1

%


5.5

%

Total prescription volume (90 Day = 1 Rx)


2.6

%


8.7

%


2.8

%


8.5

%

Total prescription volume (90 Day = 3 Rx) (1)


5.6

%


10.8

%


5.6

%


10.6

%

Same store increase (decrease):









Total sales


0.4

%


5.6

%


(0.4)%



7.0

%

Pharmacy sales


0.8

%


7.2

%


(0.8)%



8.5

%

Front store sales


(0.4)%



2.3

%


0.5

%


3.7

%

Prescription volume (90 Day = 1 Rx)


1.8

%


7.7

%


1.9

%


7.4

%

Prescription volume (90 Day = 3 Rx) (1)


5.0

%


9.8

%


4.9

%


9.5

%

Generic dispensing rate


81.9

%


79.1

%


81.6

%


78.6

%

Pharmacy % of total revenues


69.1

%


68.8

%


69.0

%


69.4

%

Third party % of pharmacy revenue


97.8

%


97.6

%


97.8

%


97.9

%

 

(1)

Includes the adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.

 

Adjusted Earnings Per Share Guidance

(Unaudited)

The following reconciliation of estimated income before income tax provision to estimated adjusted earnings per share contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-over-year performance by adjusting diluted earnings per share for amortization, which primarily relates to acquisition activities.


In millions, except per share amounts


Year Ending

December 31, 2013






Income before income tax provision


$

7,347



$

7,476


Amortization


495



495


Adjusted income before income tax provision


7,842



7,971


Adjusted income tax provision


3,054



3,111


Adjusted income from continuing operations attributable to CVS Caremark


$

4,788



$

4,860







Weighted average diluted common shares outstanding


1,229



1,227


Adjusted earnings per share from continuing operations attributable to CVS Caremark


$

3.90



$

3.96







Three Months Ending

September 30, 2013






Income before income tax provision


$

1,888



$

1,942


Amortization


125



125


Adjusted income before income tax provision


2,013



2,067


Adjusted income tax provision


781



800


Adjusted income from continuing operations attributable to CVS Caremark


$

1,232



$

1,267







Weighted average diluted common shares outstanding


1,234



1,233


Adjusted earnings per share from continuing operations attributable to CVS Caremark


$

1.00



$

1.03


 

Free Cash Flow Guidance

(Unaudited)

The following reconciliation of net cash provided by operating activities to free cash flow contains forward-looking information that is subject to risks and uncertainties that could cause actual results to differ materially. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2012 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. For internal comparisons, management finds it useful to assess year-over-year cash flow performance by adjusting cash provided by operating activities, by capital expenditures and proceeds from sale-leaseback transactions.


In millions


Year Ending

December 31, 2013






Net cash provided by operating activities


$

6,350



$

6,550


Subtract: Additions to property and equipment


(2,200)



(2,000)


Add: Proceeds from sale-leaseback transactions


600



500


Free cash flow


$

4,750



$

5,050


 


 

SOURCE CVS Caremark Corporation



RELATED LINKS
http://info.cvscaremark.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.